Drug Trial Radar · NCT05754853
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Apr 6, 2023
Primary completion
Oct 2025
Study completion Jan 2027
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.
Conditions
- Advanced or Metastatic Urothelium Cancer
Interventions
MRG002Drug
Administrated intravenously
Docetaxel InjectionDrug
Administrated intravenously
Paclitaxel InjectionDrug
Administrated intravenously
Gemcitabine Hydrochloride for InjectionDrug
Administrated intravenously
Pemetrexed Disodium InjectionDrug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Baseline to study completion (up to 36 months)
- Progression-Free Survival (PFS) by Independent Review Committee (IRC)Time frame: Baseline to study completion (up to 36 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.